Ign/1653

OLP E RESIDENCE ON IT

NITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: NISHIZAWA=3 In re Application of: Conf. No.: 5980 Toshiki NISHIZAWA Art Unit: Not Yet Known U.S. Appln. No.: 10/551,692 Examiner: Not Yet Known Filed: September 30, 2005 I.A. No.: PCT/JP04/04460 Washington D.C. I.A. Filed: March 29, 2004 October 10, 2006 For: POLYPEPTIDES

## INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.
- 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office,

either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

- 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 4. Other information being provided for the examiner's consideration follows:

## Supplementary Partial European Search Report mailed Sept. 1, 2006

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:

Sheridan Neimark

Registration No. 20,520


SN:ma

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

g:\bn\s\suma\nishizawa3\pto\2006-10-10 IDS Form.doc



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Sheet

Application Number	10/551,692	
Filing Date	September 30, 2005	
First Named Inventor	Toshiki ZISHIZAWA	
Confirmation No.	5980	
Examiner Name	Not Yet Known	
Attorney Docket Number	NISHIZAWA=3	

Complete if Known

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code <sup>2 (ri</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-		-		
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite	Foreign Patent Number  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
initiais		WO 01/81426 A2	11-01-2001	MALLINCKRODT, INC.		

	NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²		
	AB	Akira YANO et al., "An ingenious design for peptide vaccines", Vaccine, Vol. 23, pp. 2322-2326, March 18, 2005.			
	AC	Akira YANO et al., "RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following antranasal immunization", Vaccine, Vol. 22, pp. 237-243, December 12, 2003.			
	AD	Q. ZHANG et al., "Immunogenicity of a recombinant fusion protein of tandem repeat epitopes of foot-and-mouth disease virus type Asia 1 for guinea pigs", <u>Acta Virologica</u> , Vol. 46, pp. 1-9, 2002.			
	AE	Oishi Y. ONOZUKA et al., "The effect of amino acid spacers on the antigenicity of dimeric peptide-inducing cross-reacting antibodies to a cell surface protein antigen of <i>Streptococcus mutans</i> ", Oral Microbiology and Immunology, Vol. 16, No. 1, pp. 40-44, February 2001.			

Examiner	Date	
Signature	Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached.